Free shipping on all orders over $ 500

Brincidofovir

Cat. No. M13372

All AbMole products are for research use only, cannot be used for human consumption.

Brincidofovir Structure
Synonym:

CMX001; HDP-CDV

Size Price Availability Quantity
1mg USD 60  USD60 In stock
5mg USD 140  USD140 In stock
10mg USD 220  USD220 In stock
25mg USD 440  USD440 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Brincidofovir (CMX001), a lipid-coupled precursor compound of Cidofovir, has long-lasting antiviral effects and is active against a wide range of DNA viruses. These include cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomavirus, papillomavirus, poxvirus, and mixed double-stranded DNA virus infections.


In vivo experiment: (for reference only)

Brincidofovir (CMX001) was suspended in 0.4% carboxymethylcellulose (CMC) for oral delivery to mice. Acyclovir (ACV) was weighed and suspended in sterile water for oral treatment of mice. Compounds were prepared in a 0.2 ml volume which was administered once daily (CMX001) or twice daily (ACV). Treatments for efficacy evaluations were administered to mice for 7 consecutive days beginning 24-72 h post viral inoculation by oral gavage using doses of 5, 2.5 and 1.25 mg/kg of CMX001 administered once daily or doses of 120, 60 or 30 mg/kg of ACV given twice daily at approximately 12 h intervals. For pathogenesis experiments, treatments began 24 h post viral inoculation and were administered for 7 consecutive days using 5 mg/kg of CMX001 or 100 mg/kg of ACV. These doses were selected based upon the results obtained in the mortality experiments.

Chemical Information
Molecular Weight 561.69
Formula C27H52N3O7P
CAS Number 444805-28-1
Storage -20°C
References

[1] Kirk Chan-Tack, et al. Antiviral Res. Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation

[2] Christina L Hutson, et al. mSphere. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model

[3] Julio J Alvarez-Cardona, et al. Future Microbiol. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections

[4] Joshua A Hill, et al. Blood. Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT

[5] Debra C Quenelle, et al. J Infect Dis . Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

[6] Scott Parker, et al. Antiviral Res. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model

Related Anti-infection Products
Torcitabine

Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection research. Torcitabine (2'-Deoxy-L-cytidine) shows greater inhibition of first strand than second strand DNA synthesis.

ABMA

ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite.

DDX3-IN-1

DDX3-IN-1 is a DEAD-box polypeptide 3 (DDX3) inhibitor with CC50 values of 50 and 36 μM for HIV and HCV, respectively. DDX3-IN-1 has antiviral activity.

WU-04 

WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein.

MM3122 

MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Brincidofovir, CMX001; HDP-CDV supplier, Anti-infection, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.